TEMOZOLOMIDA ACCORD 140mg capsules medication leaflet

L01AX03 temozolomide • Antineoplastic and immunomodulating agents | Alkylating agents | Other alkylating agents

Temozolomide is a chemotherapy agent used for the treatment of certain types of brain tumors, such as glioblastoma multiforme and anaplastic astrocytoma. It works by interfering with the DNA of tumor cells, thereby inhibiting their growth and division.

The medication is taken orally, usually once daily, as directed by a doctor. The dosage is adjusted based on body weight and the patient's overall condition.

Patients should be monitored for potential side effects, such as nausea, vomiting, or a decrease in blood cell counts. It is important to inform the doctor of any unusual symptoms.

Common side effects include nausea, vomiting, fatigue, and loss of appetite. In rare cases, severe reactions such as myelosuppression or serious infections may occur. Patients should be informed of these risks before starting treatment.

General data about TEMOZOLOMIDA ACCORD 140mg

Substance: temozolomide

Date of last drug list: 10-04-2026

Commercial code: W65712002

Concentration: 140mg

Pharmaceutical form: capsules

Quantity: 5

Product type: generic

Price: 428.53 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: ACCORD HEALTHCARE LIMITED - MAREA BRITANIE

Holder: ACCORD HEALTHCARE S.L.U. - SPANIA

Number: 615/2010/031

Shelf life: 2 years

Pharmaceutical forms available for temozolomide

Concentrations available for temozolomide

100mg, 140mg, 180mg, 2.5mg/ml, 20mg, 240mg, 250mg, 5mg
PDF icon EMA leaflet
Published: 26/03/2010
Updated: 02/06/2025

Other substances similar to temozolomide

Compensation lists for TEMOZOLOMIDA ACCORD 140mg ACCORD

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

428.53 RON

417.98 RON

10.55 RON